Cargando…

Complement Inhibition for the Treatment of Myasthenia Gravis

Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80–90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mantegazza, Renato, Vanoli, Fiammetta, Frangiamore, Rita, Cavalcante, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751298/ https://www.ncbi.nlm.nih.gov/pubmed/33365280 http://dx.doi.org/10.2147/ITT.S261414

Ejemplares similares

Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy
por: Iacomino, Nicola, et al.
Publicado: (2022)

Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
por: Frangiamore, Rita, et al.
Publicado: (2021)

Development and validation of the Myasthenia Gravis TeleScore (MGTS)
por: Pasqualin, F., et al.
Publicado: (2022)

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids
por: Bortone, Federica, et al.
Publicado: (2020)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study
por: Bonanno, Silvia, et al.
Publicado: (2018)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis
por: Cavalcante, Paola, et al.
Publicado: (2011)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Current Treatment of Myasthenia Gravis
por: Alhaidar, Mohammed K., et al.
Publicado: (2022)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
por: Hoffmann, Sarah, et al.
Publicado: (2020)

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
Publicado: (1978)

Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations
por: Creary, Lisa E., et al.
Publicado: (2021)

The epidemiology of myasthenia gravis
por: Bubuioc, Ana-Maria, et al.
Publicado: (2021)

Diagnosis of Myasthenia Gravis
por: Rousseff, Rossen T.
Publicado: (2021)

Advances and challenges in the treatment of myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2021)

Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab
por: Damato, Valentina, et al.
Publicado: (2023)

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization
por: Iacomino, Nicola, et al.
Publicado: (2023)

Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy
por: Antonini, Giovanni, et al.
Publicado: (2023)

Immunoblot analysis of antiAChR antibodies in myasthenia gravis
por: Mantegazza, R., et al.
Publicado: (1988)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Current and emerging treatments for the management of myasthenia gravis
por: Sathasivam, Sivakumar
Publicado: (2011)

Treatment of Myasthenia Gravis Based on Its Immunopathogenesis
por: Kim, Jee Young, et al.
Publicado: (2011)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Novel Immunotherapies for Myasthenia Gravis
por: Nair, Sruthi S, et al.
Publicado: (2023)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

An update on treatments in myasthenia gravis
por: Jones, Lliwen A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o1saetas81ckumu91qjarkls5d